GlassScriptPhysician profile
Amanda Bader
NPI 1255696001
$1,861.07
in general payments reported to CMS, 2019-2025
17 companies · $522 in 2025
The $522 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $197 · 2023: $373 · 2024: $398 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $348.84 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $288.73 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $244.33 | 2021-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.25 | 2021-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $163.60 | 2021-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $154.07 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $108.07 | 2025 | Rexulti |
| Abbvie INC. | $78.70 | 2021-2025 | |
| Amarin Pharma, INC. | $78.09 | 2021 | |
| Merck Sharp & Dohme LLC | $63.19 | 2021-2025 | Vaxneuvance, Capvaxive, Enflonsia |
| Dexcom, INC. | $38.60 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $37.78 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.98 | 2023 | |
| Biogen, INC. | $19.80 | 2022 | |
| Lundbeck LLC | $15.48 | 2025 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $12.20 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $8.36 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.